Skip to main content
Premium Trial:

Request an Annual Quote

PredictImmune Wins £100K Grant for Study of IBD Prognostic

NEW YORK (GenomeWeb) — PredictImmune announced today that it has received a £100,000 ($126,368) grant from Innovate UK to investigate the use of its PredictSure IBD inflammatory bowel disease test to guide patient treatment decisions.

The test, a 15-biomarker quantitative PCR panel that runs on Roche's LightCycler instrument, is used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness. It received CE marking earlier this month and is set to launch in January.

With the Innovate UK award, Cambridge, UK-based PredictImmune said it will conduct a feasibility study examining the use of biomarkers to predict IBD patient response to new and existing treatments. The company said the trial is expected to lay the groundwork for future studies run in collaboration with undisclosed pharmaceutical partners.

"The commercially driven feasibility studies using our prognostic test for IBD … will identify which patients will benefit from the early use of more aggressive treatments and which treatment they will best respond to," PredictImmune CEO Paul Kinnon said in a statement. "The study takes us a step closer to achieving our goal of personalized medicine in IBD."

In April, PredictImmune said it received £4.3 million from the Wellcome Trust to evaluate the use of its test to guide therapy in 400 Crohn's disease patients across the UK. It also recently launched a joint study with the Crohn's & Colitis Foundation to generate additional data on PredictSure IBD.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.